First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity

CONCLUSIONS: This first-in-human, phase I clinical study identified a dose and schedule of Minnelide in patients with refractory GI cancers. The primary toxicity experienced was hematologic. Evidence of efficacy of Minnelide treatment in this group of patients was observed. The DCR ranged from ~2 to 6 months in 14/28 (50%) of evaluable patients. Studies in monotherapy and combination treatments are underway.PMID:38169017 | DOI:10.1093/oncolo/oyad278

Source: The Oncologist - January 3, 2024 Category: Cancer & Oncology Authors: Erkut Borazanci Ashok Saluja Jon Gockerman Mohana Velagapudi Ronald Korn Daniel Von Hoff Ed Greeno Source Type: research